Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: Findings from a case series

Onkologie

Volumn 28, Issue 11, 2005, Pages 558-564

  Ardavanis, Alexandros ^a   Tryfonopoulos, Dimitrios ^a   Orfanos, G ^a   Karamouzis, Mihalis ^a   Scorilas, Andreas ^b   Alexopoulos, A ^a   Rigatos, Gerassimos ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer, metastatic; Efficacy; Safety; Trastuzumab, 3 weekly

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CAPECITABINE; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; ASTHENIA; AXILLARY VEIN; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHEMA; FEMALE; HAND FOOT SYNDROME; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; HYPERSENSITIVITY REACTION; HYPOKALEMIA; HYPOTENSION; INTRAOCULAR HEMORRHAGE; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; ONCOGENE NEU; ONYCHOLYSIS; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VEIN DISEASE; VEIN THROMBOSIS;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; GREECE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 27244442145     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088608     Document Type: Article

References (30)

1. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that overexpressed HER2. J Clin Oncol 1999;17:2639-2648.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart DJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
4. Jones RL, Smith IE: Efficacy and safety of trastuzumab. Expert Opin Drug Saf 2004;3:317-327.
5. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.
6. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-4289.
7. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14: 737-744.
8. Harris K, Washington CB, Lieberman G, Lu J-F, Mass R, Bruno R: A population pharmacokinetic model for Herceptin and implications for clinical dosing. Proc Am Soc Clin Oncol 2002;21:123a (abstr 488).
9. Charoin JE, Jacqmin P, Banken L, Lennon S, Jorga K: Population pharmacokinetic analysis of trastuzumab (Herceptin) following long-term administration using different regimens. Population Approach Group (PAGE) 2004, Uppsala. http://www.page-meeting.org/default.asp?id=24&keuze=abstract- view&goto-abstracts&orderby=author&abstract_id=489.
10. Leyland-Jones B, Gelmon K, Ayoub J-P, Arnold A, Verma S, Dias R, Ghahramani P: Pharmacokinetics, safety, and efficacy of trastuzumab administered every 3 weeks in combination with paclitaxel. J Clin Oncol 2003;21:3965-3971.
11. Stewart JA, Fehrenbacher L, Blanchard RA, Rodriguez GI, Vogel CL, Anavekar P: Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+ metastatic breast cancer. Proc Am Soc Clin Oncol 2004;23:78 (abstr 806).
12. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-2831.
13. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y: Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002;49: 211-216.
14. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251.
15. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN: Phase II trial of weekly docetaxel and trastuzumab for patients with HER2 overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
16. Montemurro F, Choa G, Faggiuolo R, Donadio M, Minischetti M, Durando A, Capaldi A, Vietti-Ramus G, Alabiso O, Aglietta M: A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004;66:38-45.
17. Bernardo G, Palumbo R, Bernardo A, Villani G, Melazzini M, Poggi G, Frascaroli M, Jedrychowska I: Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 2004;23:59 (abstr 731).
18. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-2895.
19. Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L: Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 2002;7:410-417.
20. Xu L, Song S, Zhu J, Luo R, Li L, Jiao S, Pan H, Tao M, Su Y, Liu D, Chen L, et al: Capecitabine (X) combined with trastuzumab (H) as first-line therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC). Ann Oncol 2004;15(suppl 3):38 (abstr 141).
21. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2004;9(suppl 2):3-8.
22. Ahn JH, Kim SB, Kim TW, Ahn SH, Kim SM, Park JM, Lee JS, Kang YK, Kim WCapecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 2004;19:547-553.
23. Kanard A, Jatoi A, Castillo R, Geyer S, Schulz TK, Fitch TR, Rowland KM, Nair S, Krook JE, Kugler JW: Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: A phase II trial of efficacy and toxicity. Lung Cancer 2004;43:345-353.
24. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic cooperative oncology group. Clin Breast Cancer 2003;4:120-125.
25. Eisenhauer EA, Vermorken JM: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30.
26. Vassilomanolakis M, Koumakis G, Drufakou S, Aperis G, Demiri M, Barbounis V, Missitzis J, Efremidis AP: Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 2003;51:179-183.
27. Mare M, Maisano R, Caristi N, Adamo V, Altavilla G, Carboni R, Munao S, La Torre F: Venous damage prevention by defibrotide in vinorelbine-treated patients. Support Care Cancer 2003;11:593-596.
28. Cobleigh M, Frame D: Is trastuzumab every three weeks ready for prime time? J Clin Oncol 2003;21: 3900-3901.
29. Ardavanis A, Alexopoulos A, Lainakis G, Rigatos G: Three-weekly trastuzumab plus chemotherapy in HER2-postive recurrent breast cancer. Proc Am Soc Clin Oncol 2004;23:86 (abstr 842).
30. Ardavanis A, Alexopoulos A, Tryfonopoulos D, Lainakis G, Rigatos G: Evidence of safety and efficacy of trastuzumab every three weeks in combination with cytotoxic chemotherapy in HER2-positive recurrent breast cancer. Presented at the 5th Madrid Breast Cancer Conference, Madrid, 11-13 June 2003.